<DOC>
	<DOCNO>NCT02162446</DOCNO>
	<brief_summary>The purpose study assess safety tolerability 68Ga-OPS202 used diagnosis gastroenteropancreatic neuroendocrine tumor ( GEP NETs ) .</brief_summary>
	<brief_title>68Ga-OPS202 Study Diagnostic Imaging GEP NET</brief_title>
	<detailed_description />
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Intestinal Neoplasms</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<criteria>A diagnostic CT MRI tumor region within previous 6 month prior dose day available . A somatostatin receptor scan result previous 6 month prior dose day . At least 1 lesion detect previous somatostatin receptor scan . Not exceed 30 lesion / organ detect previous somatostatin receptor scan . Blood test result follow ( WBC : ≥ 3*109/L , Hemoglobin : ≥ 8.0 g/dL , Platelets : ≥ 50x109/L , ALT , AST , AP : ≤ 5 time ULN , Bilirubin : ≤ 3 time ULN ) ECG : abnormality clarify cardiologist . Serum creatinine : within normal limit &lt; 120 μmol/L patient age 60 year old . Calculated GFR ≥ 45 mL/min . Negative pregnancy test woman capable childbearing . Known hypersensitivity 68Ga , NODAGA , JR11 excipients 68GaOPS202 . History , current active allergic autoimmune disease , include asthma condition require longterm use corticosteroid . Presence active infection screen history serious infection within previous 6 week . Known human immunodeficiency virus ( HIV ) positive serology HIV , hepatitis B C. Any condition precludes raise arm position prolong imaging purpose . Neuroendocrine tumor specific treatment last somatostatin receptor image start study . Exception therapeutic use somatostatin analog ( see ) . Therapeutic use somatostatin analog , include Sandostatin® LAR ( within 28 day ) Sandostatin® ( within 2 day ) prior study imaging . If patient Sandostatin® LAR washout phase 28 day require injection study drug . If patient Sandostatin® washout phase 2 day require injection study drug . Administration another investigational medicinal product within 30 day prior entry . Prior plan administration radiopharmaceutical within 8 halflives radionuclide used radiopharmaceutical include time current study . Current &gt; grade 2 toxicity previous standard investigational therapy , per USNCI `` Common Terminology Criteria Adverse Events v4.0 '' . Pregnant breastfeed woman . History somatic psychiatric disease/condition may interfere objective assessment study . Clinically significant illness clinically relevant trauma within 2 week administration investigational product . Current history malignancy ; patient secondary tumor remission &gt; 5 year include .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>